These risks and uncertainties include, but are not limited to, the timing and logistical considerations related to updating access to the semaglutide offerings available on our platform (branded and compounded), and the related customer response
And given that the oral versions of GLP-1s offer no significant pricing difference from injectables for employers, their availability doesn't necessarily make the economics more favorable for companies, Barner added
Despite the encouraging results of GLP-1/glucagon co-agonism in experimental models, different GLP-1 and glucagon co-agonists have shown various levels of efficacy and tolerability in people with obesity and/or T2D, in early phase clinical trials, which may be explained by the different ratio of GLP-1 to glucagon activity between the different molecules [65]
2 T2D can cause serious complications, including neuropathy, retinopathy, nephropathy (kidney damage), and cardiovascular disease
[DOI] [PMC free article] [PubMed] [Google Scholar] 26.Guo J, Zhang H, Lin W, Lu L, Su J, Chen X